Literature DB >> 22672568

A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.

J A Heit1, S M Armasu, Y W Asmann, J M Cunningham, M E Matsumoto, T M Petterson, M De Andrade.   

Abstract

OBJECTIVES: To identify venous thromboembolism (VTE) disease-susceptibility genes. PATIENTS AND METHODS: We performed in silico genome wide association scan (GWAS) analyses using genotype data imputed to approximately 2.5 million single-nucleotide polymorphisms (SNPs) from adults with objectively-diagnosed VTE (n=1503), and controls frequency matched on age and gender (n=1459; discovery population). Single-nucleotide polymorphisms exceeding genome-wide significance were replicated in a separate population (VTE cases, n=1407; controls, n=1418). Genes associated with VTE were re-sequenced.
RESULTS: Seven SNPs exceeded genome-wide significance (P<5×10(-8)): four on chromosome 1q24.2 (F5 rs6025 [factor V Leiden], BLZF1 rs7538157, NME7 rs16861990 and SLC19A2 rs2038024) and three on chromosome 9q34.2 (ABO rs2519093 [ABO intron 1], rs495828, rs8176719 [ABO blood type O allele]). The replication study confirmed a significant association of F5, NME7 and ABO with VTE. However, F5 was the main signal on 1q24.2 as only ABO SNPs remained significantly associated with VTE after adjusting for F5 rs6025. This 1q24.2 region was shown to be inherited as a haplotype block. ABO re-sequencing identified 15 novel single nucleotide variations (SNV) in ABO intron 6 and the ABO 3' UTR that were strongly associated with VTE (P<10(-4)) and belonged to three distinct linkage disequilibrium (LD) blocks; none were in LD with ABO rs8176719 or rs2519093. Our sample size provided 80% power to detect odds ratios (ORs)=2.0 and 1.51 for minor allele frequencies=0.05 and 0.5, respectively (α=1×10(-8); 1% VTE prevalence).
CONCLUSIONS: Apart from F5 rs6025, ABO rs8176719, rs2519093 and F2 rs1799963, additional common and high VTE-risk SNPs among whites are unlikely.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672568      PMCID: PMC3419811          DOI: 10.1111/j.1538-7836.2012.04810.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  50 in total

Review 1.  P-selectin in haemostasis.

Authors:  Patrick André
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

2.  Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures.

Authors:  T Matsui; K Titani; T Mizuochi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

3.  A Hidden Markov Model approach to variation among sites in rate of evolution.

Authors:  J Felsenstein; G A Churchill
Journal:  Mol Biol Evol       Date:  1996-01       Impact factor: 16.240

4.  Heightened thrombin generation in individuals with resistance to activated protein C.

Authors:  I Martinelli; B Bottasso; F Duca; E Faioni; P M Mannucci
Journal:  Thromb Haemost       Date:  1996-05       Impact factor: 5.249

5.  Characterization of the molecular defect in factor VR506Q.

Authors:  M Kalafatis; R M Bertina; M D Rand; K G Mann
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

6.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

7.  Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins.

Authors:  Torben Bjerregaard Larsen; Henrik Toft Sørensen; Axel Skytthe; Søren Paaske Johnsen; James W Vaupel; Kaare Christensen
Journal:  Epidemiology       Date:  2003-05       Impact factor: 4.822

8.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

9.  Familial segregation of venous thromboembolism.

Authors:  J A Heit; M A Phelps; S A Ward; J P Slusser; T M Petterson; M De Andrade
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

10.  Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom
Journal:  Am J Med       Date:  2002-12-01       Impact factor: 4.965

View more
  65 in total

1.  The phenotypic legacy of admixture between modern humans and Neandertals.

Authors:  Corinne N Simonti; Benjamin Vernot; Lisa Bastarache; Erwin Bottinger; David S Carrell; Rex L Chisholm; David R Crosslin; Scott J Hebbring; Gail P Jarvik; Iftikhar J Kullo; Rongling Li; Jyotishman Pathak; Marylyn D Ritchie; Dan M Roden; Shefali S Verma; Gerard Tromp; Jeffrey D Prato; William S Bush; Joshua M Akey; Joshua C Denny; John A Capra
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

2.  Prospective study of γ' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Weihong Tang; Kristen M George; Susan R Heckbert; Richard F MacLehose; Mary Cushman; James S Pankow
Journal:  Thromb Res       Date:  2016-01-12       Impact factor: 3.944

3.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

4.  Taller height as a risk factor for venous thromboembolism: a Mendelian randomization meta-analysis.

Authors:  N S Roetker; S M Armasu; J S Pankow; P L Lutsey; W Tang; M A Rosenberg; T M Palmer; R F MacLehose; S R Heckbert; M Cushman; M de Andrade; A R Folsom
Journal:  J Thromb Haemost       Date:  2017-06-06       Impact factor: 5.824

5.  Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study.

Authors:  Virginia M Miller; Tanya M Petterson; Elysia N Jeavons; Abhinita S Lnu; David N Rider; John A Heit; Julie M Cunningham; Gordon S Huggins; Howard N Hodis; Matthew J Budoff; Nanette Santoro; Paul N Hopkins; Rogerio A Lobo; JoAnn E Manson; Frederick Naftolin; Hugh S Taylor; S Mitchell Harman; Mariza de Andrade
Journal:  Physiol Genomics       Date:  2012-11-27       Impact factor: 3.107

Review 6.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

7.  Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism.

Authors:  Cynthia Wu; Dhruva J Dwivedi; Laura Pepler; Zakhar Lysov; John Waye; Jim Julian; Karl Desch; David Ginsburg; Jeffrey I Weitz; Clive Kearon; Patricia C Liaw
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-09-19       Impact factor: 8.311

8.  Interaction of a genetic risk score with physical activity, physical inactivity, and body mass index in relation to venous thromboembolism risk.

Authors:  Jihye Kim; Peter Kraft; Kaitlin A Hagan; Laura B Harrington; Sara Lindstroem; Christopher Kabrhel
Journal:  Genet Epidemiol       Date:  2018-03-08       Impact factor: 2.135

9.  The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

Authors:  Ari Allyn-Feuer; Alex Ade; Jasmine A Luzum; Gerald A Higgins; Brian D Athey
Journal:  Pharmacogenomics       Date:  2018-02-05       Impact factor: 2.533

10.  Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Alvaro Alonso; Kristen M George; Nicholas S Roetker; Weihong Tang; Mary Cushman
Journal:  Thromb Res       Date:  2015-08-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.